A5090729537- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- HER2/EGFR in Cancer Research
- Male Breast Health Studies
- Multiple and Secondary Primary Cancers
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Ubiquitin and proteasome pathways
- Radiopharmaceutical Chemistry and Applications
- Protein Kinase Regulation and GTPase Signaling
- Fibroblast Growth Factor Research
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- RNA modifications and cancer
- Tannin, Tannase and Anticancer Activities
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Monoclonal and Polyclonal Antibodies Research
Mayo Clinic
2017-2025
Mayo Clinic in Arizona
2016-2025
WinnMed
2023-2025
John Wiley & Sons (United States)
2020
University of California, San Francisco
2014
University of Pittsburgh
2008-2010
Background Male breast cancer (MBC) is a rare disease for which there limited understanding of treatment patterns and prognostic factors. Methods Men with TNM stage I to III diagnosed between 2004 2014 in the National Cancer Data Base were included. Trends modalities described using average annual percentage change (AAPC) estimated Joinpoint software analysis trends. Kaplan‐Meier curves multivariate Cox proportional hazards regression model used compare survival subgroups identify Results A...
Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, implicated cyclin-dependent 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective inhibitor, upregulates ERα restores sensitivity preclinical metastatic breast cancer (MBC) models. The safety preliminary efficacy alisertib was demonstrated early-phase trials; however, its activity CDK 4/6i-resistant MBC unknown.
Abstract Introduction. T-DXd is FDA-approved for patients (pts) with hormone receptor positive (HR+) or HR- HER2-low (IHC 1+ 2+, ISH-) MBC and SG pts HR+/HER2- triple negative MBC. However, several outstanding questions impact the use of these drugs in clinic, including: 1) what efficacy safety agents real-world populations diverse pt characteristics not well represented pivotal phase III trials, 2) sequential treatment ADCs on agents. Methods. In this multicenter retrospective cohort study,...
Abstract Purpose: The aim of PREDICT was to confirm clinical validity and the potential for utility serial circulating tumor cell (CTC) enumeration in metastatic breast cancer (MBC) patients focusing on its prognostic value different subtypes settings. Experimental design: In total, 4436 individual patient-level data with CTC results from both baseline one follow-up (CellSearch®; Menarini Silicon Biosystems) were analyzed evaluate association between detection overall survival (OS) full...
Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by the second messenger diacylglycerol. It has been implicated in many important cellular processes and pathological conditions. However, further analysis PKD these severely hampered lack PKD-specific inhibitor that can be readily applied to cells animal models. We now report discovery first potent selective cell-active small molecule for PKD, benzoxoloazepinolone (CID755673). This was identified from National...
Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, accounted 93.1% the mapped RNAs. 227 with high abundance selected survival analysis. Cox regression analysis identified association 6 overall (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five associated quantified independent follow-up cohort 65 mRCC TaqMan-based miRNA assays. Kaplan-Meier confirmed...
Protein kinase D (PKD) has been implicated in a wide range of cellular processes and pathological conditions including cancer. However, targeting PKD therapeutically dissecting PKD-mediated responses remains difficult due to lack potent selective inhibitor. Previously, we identified novel pan-PKD inhibitor, CID755673, with potency the upper nanomolar high selectivity for PKD. In an effort further enhance its potential vivo application, small molecule analogs CID755673 were generated by...
1083 Background: T-DXd and SG are both FDA-approved treatments for patients (pts) with HER2-low MBC, but little data exists on the sequential use of these ADCs. Methods: In this multicenter retrospective cohort study, we identified pts MBC treated sequentially in either order, or without intervening therapies (IntTx), at 5 academic centers between 2020-2023. We previously reported real-world progression free survival (rwPFS) overall (rwOS) by HR-status ADC sequence order. Here provide...
Abstract Introduction Structured data capture requires defined languages such as minimal Common Oncology Data Elements (mCODE). This pilot assessed the feasibility of capturing 5 mCODE categories (stage, disease status, performance status (PS), intent therapy and to change therapy). Methods A tool (SmartPhrase) using existing custom structured elements was Built 4 (disease PS, therapy) typically documented free‐text within notes. Existing functionality for stage supported by Build....
"QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data Real-Time the Electronic Health Record (EHR)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Abstract Deep learning has advanced digital pathology and multi-omics data analysis. However, there is still a critical need to integrate these modalities better understand complex diseases. models, such as Prov-Gigapath, state-of-the-art foundation model, have been developed for analyzing whole-slide images (WSI). Our previously published deep-learning framework, OmicsFootPrint (OFP), transforms high-dimensional into intuitive genomically-arranged circular utilizes transfer overcome the...
Abstract Background: Fibroblast growth factor receptor 1 (FGFR1) gene amplification and overexpression is associated with an adverse prognosis in hormone receptor–positive (HR+)/human epidermal 2–negative (HER2−) breast cancer observed ~10% of all invasive cancers. The phase 2 FOENIX-MBC2 study (NCT04024436) was designed to evaluate the effect futibatinib, a highly selective potent irreversible covalent inhibitor FGFR1–4 (FDA-approved for intrahepatic cholangiocarcinoma), used either alone...
Abstract Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 HER2-low MBC treated sequentially trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in either order at 5 institutions between 2020–2024. We evaluated clinical parameters associated time to treatment failure (TTF) real-world overall...
Abstract Background: Endocrine therapy (ET) with aromatase inhibitors (AI) plus ovarian function suppression (OFS) is standard for premenopausal women ER+/HER2- breast cancer. However, many are intolerant of AI + OFS, leaving tamoxifen (with or without OFS) as their only option. Extensive studies have demonstrated that treated neoadjuvant ET whose tumors exhibit Ki-67 ≤ 10% following 4 weeks (defined endocrine sensitive disease (ESD)) achieve 5-year distant disease-free survival &gt;...
Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) induce apoptosis in many tumor cells including the androgen-sensitive LNCaP prostate cancer cells. Although ester-induced apoptotic pathways have been well characterized, little is known of pro-survival modulated by these agents. We now provide experimental evidence to indicate that protein kinase D (PKD) promotes survival signals response PMA treatment. Knockdown endogenous PKD1 or PKD2 decreased extracellular signal-regulated...
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide the neoadjuvant treatment of breast cancer. Ganitumab a monoclonal antibody designed to bind inhibit function type I insulin-like growth factor receptor (IGF-1R). was tested metformin (PGM) AC compared alone. While pathologic complete response (pCR) rates were numerically higher PGM arm for hormone receptor-negative,...